undamentalytics Newsletter
Sign in

ResMed| cash flow statement

In fiscal 2026, ResMed|'s operations generated $1.81bn of cash; it spent $156m on capital projects, leaving free cash flow of $1.65bn. It returned $350m in dividends and $700m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Jun 20102011Jun 20112012Jun 20122013Jun 20132014Jun 20142015Jun 20152016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026LTMSept 2026
Cash from operations1882833834033913835484145054598027373516931,4011,7521,8061,771
Depreciation and amortisation62718678737387112120151155157160165177198201195
Stock-based pay30313138434846464852586465718092104113
Capital spending57674764736359626369951031351209990156162
Free cash flow1312173363393193214893524423907076342165741,3021,6621,6501,609
Free cash flow after stock pay1021863053012752734433063943386495701515021,2221,5701,5451,496
Dividends paid———97142157168186199212225227245258282311350357
Share buybacks131163393186202160102—5423——001503007001,486
Shares issued959562693339283839374838474953747570

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: RMD vs STEBLCO vs RMDDXCM vs RMDEW vs RMD

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from ResMed|'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ResMed|.